AtaiBeckley Inc

ATAI

Market cap $2.63B

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley will receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments u.

Lulu's Fashion Lounge Holdings (NASDAQ:LVLU) retained Solomon Partners as its financial advisor and Willkie Farr & Gallagher LLP as its legal advisor as the company evaluates strategic alternatives to maximize shareholder value. Alternatives may include a potential transaction or continued execution of Lulu's standalone strategic plan.

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop. The acquisition, previously announced by Lilly, values AtaiBeckley at $6.75 per share in cash, or about $2.8 billion in equity, plus a contingent value right of up to $2.50 per share, worth roughly $1 billion if certain milestones are achieved.

AtaiBeckley is developing a promising depression treatment. Eli Lilly has long been a leader in neuroscience.

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating AtaiBeckley Inc. (NASDAQ: ATAI ) related to its sale to Eli Lilly and Company.

AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has agreed to pay $6.75 a share in cash upfront ($2.8 billion) – with an additional $2.5 a share in contingent value rights (CVRs) tied to critical clinical and regulatory milestones.

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026.

Eli Lilly and Co (NYSE:LLY) on Thursday agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal that values the clinical-stage mental health biotechnology company at up to approximately $3.8 billion, strengthening Lilly's portfolio of rapid-acting therapies for treatment-resistant depression and other psychiatric disorders.